PT  - JOURNAL ARTICLE
AU  - SASAI, MASAO
AU  - NAKAMURA, HIROYUKI
AU  - SOUGAWA, NAGAKO
AU  - SAKURAI, YOSHINORI
AU  - SUZUKI, MINORU
AU  - LEE, CHUN MAN
TI  - Novel Hyaluronan Formulation Enhances the Efficacy of Boron Neutron Capture Therapy for Murine Mesothelioma
DP  - 2016 Mar 01
TA  - Anticancer Research
PG  - 907--911
VI  - 36
IP  - 3
4099  - http://ar.iiarjournals.org/content/36/3/907.short
4100  - http://ar.iiarjournals.org/content/36/3/907.full
SO  - Anticancer Res2016 Mar 01; 36
AB  - Background: Malignant pleural mesothelioma (MPM) is a refractory cancer of the pleura caused by asbestos exposure. MPM is difficult to treat because it easily disseminates. Boron neutron capture therapy (BNCT) is a radiotherapy in which cancer cells that selectively take up 10Boron-containing compounds are destroyed, and normal cells are uninjured. Hyaluronan (HA) is a ligand of cluster of differentiation 44 (CD44), that is expressed on MPM cells. Materials and Methods: In order to enhance BNCT for MPM tumors, we developed a novel HA-containing 10B (sodium borocaptate: BSH) formulation (HA-BND-S). We examined the efficacy of HA-BND-S using MPM cells and a mouse MPM model. Results: HA-BND-S preferentially bound MPM cells dose-dependently, and increased the cytotoxicity of BNCT compared to BSH in vitro. HA-BND-S administration significantly increased the survival of MPM tumor-bearing mice compared to BSH at the same 10B dosage in BNCT. Conclusion: Modifying BSH with HA is a promising strategy for enhancing the efficacy of BNCT for therapy of MPM.